SYRS - Syros Pharmaceuticals Inc.
IEX Last Trade
1.64
-0.020 -1.220%
Share volume: 113,162
Last Updated: Fri 30 Aug 2024 09:59:53 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.66
-0.02
-1.21%
View ratios
| Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-11-14 | 2023-03-02 | 2023-05-10 | 2023-08-08 | 2023-11-14 | 2024-03-27 | 2024-05-14 | 2024-07-31 | |
| Total revenue | 3.891 M | -754.000 K | 2.954 M | 2.833 M | 3.762 M | 387.000 K | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 3.891 M | -754.000 K | 2.954 M | 2.833 M | 3.762 M | 387.000 K | 0.000 | 0.000 | |
| -119.38% | 491.78% | -4.10% | 32.79% | -89.71% | -100.00% | nan% | |||
| Operating expenses | 33.835 M | 35.243 M | 36.166 M | 36.833 M | 36.044 M | 27.392 M | 30.921 M | 27.416 M | |
| Selling general and admin | 8.076 M | 7.329 M | 7.405 M | 7.225 M | 7.764 M | 5.888 M | 6.266 M | 5.463 M | |
| Research and development | 25.759 M | 27.914 M | 28.761 M | 29.608 M | 28.280 M | 21.504 M | 24.655 M | 21.953 M | |
| Total expenses | 33.835 M | 35.243 M | 36.166 M | 36.833 M | 36.044 M | 27.392 M | 30.921 M | 27.416 M | |
| 4.16% | 2.62% | 1.84% | -2.14% | -24.00% | 12.88% | -11.34% | |||
| Operating income | -29.944 M | -35.997 M | -33.212 M | -34.000 M | -32.282 M | -27.005 M | -30.921 M | -27.416 M | |
| Ebit | -29.944 M | -35.997 M | -33.212 M | -34.000 M | -32.282 M | -27.005 M | -30.921 M | -27.416 M | |
| Pretax income | -30.253 M | -4.774 M | -23.789 M | -36.258 M | -40.143 M | -64.384 M | -3.708 M | -23.327 M | |
| -84.22% | 398.30% | 52.41% | 10.71% | 60.39% | -94.24% | 529.10% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | -30.253 M | -4.774 M | -23.789 M | -36.258 M | -40.143 M | -64.384 M | -3.708 M | -23.327 M | |
| 84.22% | -398.30% | -52.41% | -10.71% | -60.39% | 94.24% | -529.10% | |||
| Net income | -30.253 M | -4.774 M | -23.789 M | -36.258 M | -40.143 M | -64.384 M | -3.708 M | -23.327 M | |
| 84.22% | -398.30% | -52.41% | -10.71% | -60.39% | 94.24% | -529.10% |